UCB has aquired Candid Therapeutics for $2 billion; plan to lead in autoimmune dz by acquiring cizutamig - a T cell enga

UCB has aquired Candid Therapeutics for $2 billion; plan to lead in autoimmune dz by acquiring cizutamig - a T cell engager. Its been studied in >100 pts, including early Global Phase 2 RCTs of myasthenia gravis & ILD. https://t.co/xz4uEhvxu6 https://t.co/6FS1riLecW

Links:

UCB Just Paid $2.2 Billion for an Autoimmune Platform. The Indication List Tell… https://buff.ly/s3w3Dwe